Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 20/20 | 0.84 |
| ▸ | HSP90AB1 | P08238 | 20/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3520350 | 0.92 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1 | |
| SCHEMBL13050643 | 0.90 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1 | |
| SCHEMBL1669255 | 0.90 | HSP90AA1 (0.80) | HSP90AA1HSP90AB1 | |
| SCHEMBL3525108 | 0.89 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1 | |
| SCHEMBL13050647 | 0.88 | HSP90AA1 (0.85) | HSP90AA1HSP90AB1 | |
| SCHEMBL12304583 | 0.87 | HSP90AA1 (0.65) | HSP90AA1HSP90AB1 | |
| SCHEMBL3745517 | 0.86 | HSP90AA1 (0.86) | HSP90AA1HSP90AB1 | |
| SCHEMBL1669214 | 0.85 | HSP90AA1 (0.75) | HSP90AA1HSP90AB1 | |
| SCHEMBL3121796 | 0.85 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1 | |
| SCHEMBL13050247 | 0.85 | HSP90AA1 (0.82) | HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| EP-2219448-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN TREATING DISEASES AND DISORDERS | Myriad Pharmaceuticals, Inc. (US) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009065035-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN TREATING DISEASES AND DISORDERS | MYRIAD GENETICS, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009065035-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN TREATING DISEASES AND DISORDERS | MYRIAD GENETICS, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | VHL, CLN6, CFTR | HSP90AA1 659/4885HSP90AB1 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.